Abbvie (ABBV) PT Raised to $120 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts ABBV Hot Sheet
Price: $294.89 +1.41%
Rating Summary:
28 Buy, 10 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 8 | New: 7
Rating Summary:
28 Buy, 10 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 8 | New: 7
Join SI Premium – FREE
JPMorgan analyst Chris Schott raised the price target on Abbvie (NYSE: ABBV) to $120.00 (from $115.00) while maintaining a Overweight rating.
You May Also Be Interested In
- AbbVie (ABBV) Tops Q3 EPS by 8c, Offers Guidance
- AbbVie Reports Third-Quarter 2026 Financial Results
- Bureau Veritas SA (BVI:FP) (BVRDF) PT Raised to EUR33.91 at Citi
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
